Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Design Therapeutics Inc (DSGN)

Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 534,322
  • Shares Outstanding, K 56,964
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,590 K
  • EBIT $ -78 M
  • EBITDA $ -84 M
  • 60-Month Beta 1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.79

Options Overview Details

View History
  • Implied Volatility 228.04% (-129.60%)
  • Historical Volatility 67.92%
  • IV Percentile 56%
  • IV Rank 31.97%
  • IV High 525.69% on 04/16/25
  • IV Low 88.15% on 08/18/25
  • Expected Move (DTE 14) 0.48 (5.40%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 326
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 5,493
  • Open Int (30-Day) 2,956
  • Expected Range 8.50 to 9.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.31
  • Low Estimate -0.36
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.43 +6.38%
on 12/19/25
10.31 -12.96%
on 12/05/25
+0.03 (+0.34%)
since 12/02/25
3-Month
5.28 +69.89%
on 10/22/25
10.31 -12.96%
on 12/05/25
+2.96 (+49.13%)
since 10/02/25
52-Week
2.60 +245.00%
on 04/11/25
10.31 -12.96%
on 12/05/25
+2.80 (+45.38%)
since 01/02/25

Most Recent Stories

More News
Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 9.08 (-3.20%)
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)  Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs...

DSGN : 9.08 (-3.20%)
Design Therapeutics Appoints Justin Gover to Board of Directors

CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...

CMPS : 6.53 (-5.36%)
DSGN : 9.08 (-3.20%)
XENE : 44.01 (-1.81%)
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 9.08 (-3.20%)
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA...

DSGN : 9.08 (-3.20%)
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

DSGN : 9.08 (-3.20%)
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

DSGN : 9.08 (-3.20%)
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

DSGN : 9.08 (-3.20%)
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

DSGN : 9.08 (-3.20%)
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

DSGN : 9.08 (-3.20%)

Business Summary

Design Therapeutics Inc. is a biotechnology company. It involved in developing a platform of gene targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions. Design Therapeutics Inc. is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 10.41
2nd Resistance Point 10.14
1st Resistance Point 9.76
Last Price 9.08
1st Support Level 9.11
2nd Support Level 8.85
3rd Support Level 8.47

See More

52-Week High 10.31
Last Price 9.08
Fibonacci 61.8% 7.36
Fibonacci 50% 6.45
Fibonacci 38.2% 5.54
52-Week Low 2.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar